Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Stepen Smith, John W. Sweetenham

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalFuture Oncology
Volume3
Issue number3
DOIs
StatePublished - Jun 1 2007

    Fingerprint

Keywords

  • Bexxar®
  • I131
  • Indolent NHL
  • Radioimmunoconjugate
  • Tositumomab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this